June 05, 2010
Newer Drugs Beat Gleevec in Head-to-Head
TrialsTwo new drugs, dasatinib
(Sprycel) and nilotinib (Tasigna), appear better than imatinib
(Gleevec) in treating patients with newly diagnosed chronic myeloid
leukemia and should be considered as first-line treatments, two new
studies show.
Novel Drug Combats Advanced MelanomaScientists say that a new
drug to treat melanoma, the first in its class, improved survival
by 68 percent in patients whose disease had spread from the skin to
other parts of the body.